clinical trial · NCT05902962
SAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects
Retinal DystrophyPRPF31 Mutationassociated Retinal DystrophyRP11VP-001
brief summary
A Phase 1 Open-Label, Single Arm Dose Escalation Study to Evaluate the Safety and Tolerability of Intravitreally Administered VP-001 in Participants with Confirmed PRPF31 Mutation-Associated Retinal Dystrophy
started
Apr 20, 2023
primary completion
Aug 8, 2025
completion
Aug 8, 2025
last updated
May 29, 2026
official title
A Phase 1 Open-Label, Single Arm Dose Escalation Study to Evaluate the Safety and Tolerability of Intravitreally Administered VP-001 in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol